<DOC>
	<DOCNO>NCT02712593</DOCNO>
	<brief_summary>This study evaluate effect repeat dos Niagen™ Niagen™ metabolite concentration blood , urine muscle . There 3 dos Niagen™ compare placebo . One quarter subject receive low dose Niagen™ , one quarter receive moderate dose Niagen™ , one quarter receive high dose Niagen™ one quarter reveive placebo .</brief_summary>
	<brief_title>A Study Investigating Effects Niagen™ Healthy Adults .</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>BMI 2530kg/m² If female , subject child bear potential , defined female hysterectomy oophorectomy , bilateral tubal ligation postmenopausal ( natural surgically &gt; 1 year since last menstruation ) OR Females childbearing potential must agree use medically approve method birth control negative urine pregnancy test result . Acceptable method birth control include : Hormonal contraceptive include oral contraceptive , hormone birth control patch ( Ortho Evra ) , vaginal contraceptive ring ( NuvaRing ) , injectable contraceptive ( DepoProvera , Lunelle ) , hormone implant ( Norplant System ) Doublebarrier method Nonhormonal intrauterine device Vasectomy partner Healthy determine laboratory result , medical history , physical exam Agrees comply study procedure Agrees maintain current level physical activity throughout study avoid exercise day study visit 3 7 ( prior visit ) . Agrees refrain consume caffeine ( i.e . coffee ) day study visit 3 7 ( prior visit ) Agrees avoid take Vitamin B3 ( niacin , nicotinic acid , niacinamide ) supplement multivitamins 14 day prior randomization duration study period Has give voluntary , write , inform consent participate study Agrees avoid food contain high amount tryptophan niacin limit ingestion food contain moderate amount tryptophan niacin Women pregnant , breastfeeding , plan become pregnant course trial Alcohol use &gt; 2 standard alcoholic drink per day History alcohol drug abuse within past year Medicinal use marijuana Diabetes ( Type I Type II ) Subjects take lipid lower drug History renal and/or liver disease History pellagra niacin deficiency Significant untreated medical disorder include recent myocardial ischemia infarction , unstable angina , uncontrolled hypertension , AIDS , malignancy , neurological disorder include epilepsy , recent cerebrovascular disease Subjects recently experience traumatic injury , inflammation , infection undergo surgery Use natural health product contain NR within 14 day prior randomization course study Unstable medical condition determine Qualified Investigator Clinically significant abnormal lab result screen ( e.g . AST and/or ALT &gt; 2 x ULN , and/or bilirubin &gt; 2 x ULN ) assess Medical Investigator History current diagnosis cancer ( except successfully treat basal cell carcinoma ) diagnose less 5 year prior screen . Subjects cancer full remission 5 year diagnosis acceptable Participation clinical research trial within 30 day prior randomization Allergy sensitivity study supplement ingredient Allergy sensitivity lidocaine Bleeding disorder Serum creatinine ≥ 130µmol/L male ≥ 125µmol/L female Individuals cognitively impair and/or unable give inform consent Any condition Investigator 's opinion may adversely affect subject 's ability complete study may pose significant risk subject</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Dietary supplement</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Niagen™</keyword>
	<keyword>Nicotinamide riboside</keyword>
	<keyword>N-methylnicotinamide</keyword>
</DOC>